BACKGROUND AND OBJECTIVE: Although salsalate administration consistently lowers plasma triglyceride concentrations in patients with type II diabetes, prediabetes, and/or insulin resistance, changes in low-density lipoprotein cholesterol (LDL-C) concentrations have been inconsistent; varying from no change to a significant increase. To evaluate the clinical relevance of this discordance in more detail, we directly measured LDL-C and obtained a comprehensive assessment of changes in lipid, lipoprotein, and apoprotein concentrations associated with salsalate use in insulin-resistant individuals, overweight or obese, but without diabetes, using vertical auto profile method. METHODS: A single-blind, randomized, placebo-controlled study was performed in volunteers who were overweight or obese, without diabetes, and insulin resistant on the basis of their steady-state plasma glucose concentration during an insulin suppression test. Participants were randomized 2:1 to receive salsalate 3.5 g/d (n = 27) or placebo (n = 14) for 4 weeks. Comprehensive lipid, lipoprotein, and apoprotein analysis by vertical auto profile was obtained after an overnight fast, before and after study intervention. RESULTS: There was no change in directly measured LDL-C concentration in salsalate-treated individuals. However, salsalate administration was associated with various changes considered to decrease atherogenicity; including decreases in triglyceride and total very low-density lipoprotein cholesterol (VLDL-C) concentrations, a shift from small denser LDL lipoproteins toward larger, more buoyant LDL particles, decreases in VLDL(1+2)-C and LDL(4)-C, and nonsignificant decreases in non-high-density lipoprotein cholesterol and apolipoprotein B. No significant changes occurred in the placebo-treated group. CONCLUSIONS:Atherogenicity of the lipid, lipoprotein, and apoprotein profile of insulin-resistant individuals who were overweight or obese improved significantly in association with salsalate treatment. The clinical importance of this finding awaits further study.
RCT Entities:
BACKGROUND AND OBJECTIVE: Although salsalate administration consistently lowers plasma triglyceride concentrations in patients with type II diabetes, prediabetes, and/or insulin resistance, changes in low-density lipoprotein cholesterol (LDL-C) concentrations have been inconsistent; varying from no change to a significant increase. To evaluate the clinical relevance of this discordance in more detail, we directly measured LDL-C and obtained a comprehensive assessment of changes in lipid, lipoprotein, and apoprotein concentrations associated with salsalate use in insulin-resistant individuals, overweight or obese, but without diabetes, using vertical auto profile method. METHODS: A single-blind, randomized, placebo-controlled study was performed in volunteers who were overweight or obese, without diabetes, and insulin resistant on the basis of their steady-state plasma glucose concentration during an insulin suppression test. Participants were randomized 2:1 to receive salsalate 3.5 g/d (n = 27) or placebo (n = 14) for 4 weeks. Comprehensive lipid, lipoprotein, and apoprotein analysis by vertical auto profile was obtained after an overnight fast, before and after study intervention. RESULTS: There was no change in directly measured LDL-C concentration in salsalate-treated individuals. However, salsalate administration was associated with various changes considered to decrease atherogenicity; including decreases in triglyceride and total very low-density lipoprotein cholesterol (VLDL-C) concentrations, a shift from small denser LDL lipoproteins toward larger, more buoyant LDL particles, decreases in VLDL(1+2)-C and LDL(4)-C, and nonsignificant decreases in non-high-density lipoprotein cholesterol and apolipoprotein B. No significant changes occurred in the placebo-treated group. CONCLUSIONS: Atherogenicity of the lipid, lipoprotein, and apoprotein profile of insulin-resistant individuals who were overweight or obese improved significantly in association with salsalate treatment. The clinical importance of this finding awaits further study.
Authors: Michael Miller; Neil J Stone; Christie Ballantyne; Vera Bittner; Michael H Criqui; Henry N Ginsberg; Anne Carol Goldberg; William James Howard; Marc S Jacobson; Penny M Kris-Etherton; Terry A Lennie; Moshe Levi; Theodore Mazzone; Subramanian Pennathur Journal: Circulation Date: 2011-04-18 Impact factor: 29.690
Authors: Michael H Davidson; Christie M Ballantyne; Terry A Jacobson; Vera A Bittner; Lynne T Braun; Alan S Brown; W Virgil Brown; William C Cromwell; Ronald B Goldberg; James M McKenney; Alan T Remaley; Allan D Sniderman; Peter P Toth; Sotirios Tsimikas; Paul E Ziajka; Kevin C Maki; Mary R Dicklin Journal: J Clin Lipidol Date: 2011 Sep-Oct Impact factor: 4.766
Authors: Allison B Goldfine; Vivian Fonseca; Kathleen A Jablonski; Laura Pyle; Myrlene A Staten; Steven E Shoelson Journal: Ann Intern Med Date: 2010-03-16 Impact factor: 25.391
Authors: B Lamarche; A Tchernof; S Moorjani; B Cantin; G R Dagenais; P J Lupien; J P Després Journal: Circulation Date: 1997-01-07 Impact factor: 29.690
Authors: Seth S Martin; Michael J Blaha; Mohamed B Elshazly; Eliot A Brinton; Peter P Toth; John W McEvoy; Parag H Joshi; Krishnaji R Kulkarni; Patrick D Mize; Peter O Kwiterovich; Andrew P Defilippis; Roger S Blumenthal; Steven R Jones Journal: J Am Coll Cardiol Date: 2013-03-21 Impact factor: 24.094
Authors: Joshua W Knowles; Themistocles L Assimes; Philip S Tsao; Andrea Natali; Andrea Mari; Thomas Quertermous; Gerald M Reaven; Fahim Abbasi Journal: Metabolism Date: 2012-11-12 Impact factor: 8.694
Authors: A B Goldfine; P R Conlin; F Halperin; J Koska; P Permana; D Schwenke; S E Shoelson; P D Reaven Journal: Diabetologia Date: 2013-01-31 Impact factor: 10.122
Authors: Allison B Goldfine; Vivian Fonseca; Kathleen A Jablonski; Yii-Der Ida Chen; Laura Tipton; Myrlene A Staten; Steven E Shoelson Journal: Ann Intern Med Date: 2013-07-02 Impact factor: 25.391
Authors: Brennan K Smith; Rebecca J Ford; Eric M Desjardins; Alex E Green; Meghan C Hughes; Vanessa P Houde; Emily A Day; Katarina Marcinko; Justin D Crane; Emilio P Mottillo; Christopher G R Perry; Bruce E Kemp; Mark A Tarnopolsky; Gregory R Steinberg Journal: Diabetes Date: 2016-08-23 Impact factor: 9.461
Authors: Eric P Davidson; Lawrence J Coppey; Hanna Shevalye; Alexander Obrosov; Mark A Yorek Journal: J Diabetes Res Date: 2018-07-02 Impact factor: 4.011